YTHDF1 and neoplasm: Intriguingly, cell-intrinsic N6-methyladenosine reader protein (YTHDF1) in tumors can disrupt tumor antigens and impair immune surveillance, whereas engineered exosomes can be utilized to deliver CRISPR/Cas9 in order to specifically target tumor YTHDF1, thereby, restoring tumor immune surveillance [19].